Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACAV: Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients

NCT04193306 is registered in ClinicalTrials.gov with Institute for Clinical and Experimental Medicine as lead sponsor.

NCT NCT04193306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04193306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACAV: Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
Lead sponsor
Institute for Clinical and Experimental Medicine
Phase
Phase 4
Overall status
Unknown status
Start date
November 18, 2019
Completion date
July 31, 2025
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac allograft vasculopathy